drugset / Trial / NCT00002197

A Study of 1592U89 in HIV-Infected Children

NCT00002197

Completed 250 enrolled Glaxo Wellcome
Open-labelTreatment

Summary

The purpose of this study is to see if it is safe to give 1592U89 to children (aged 6 months until 14th birthday) with advanced HIV infection who have few treatment options available. The study also examines the effect 1592U89 has on the levels of HIV in the blood.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Abacavir Other / unclassified